NCT02691299 (FALUCA) is a Phase 3 clinical trial of Fruquintinib in NSCLC, sponsored by Hutchison Medipharma Limited.

Who is sponsoring NCT02691299?

NCT02691299 is sponsored by Hutchison Medipharma Limited.

What drugs are being tested in NCT02691299?

Interventions in NCT02691299: Fruquintinib, Placebo.

Is NCT02691299 still recruiting?

NCT02691299 is currently completed. Last updated 12 February 2019.

Last reviewed 2019-02-12 · How we verify

NCT02691299: FALUCA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Completed Phase 3 Last updated 12 February 2019

What this trial tests

Phase 3 trial testing Fruquintinib in NSCLC in 527 participants. Completed in 16 November 2018.

Timeline

9 December 2015

Primary endpoint
21 September 2018

16 November 2018

Quick facts

Lead sponsor	Hutchison Medipharma Limited
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	527
Start date	9 December 2015
Primary completion	21 September 2018
Estimated completion	16 November 2018
Sites	11 locations across China

Drugs / interventions tested

Fruquintinib — full drug profile →
Placebo

Conditions studied

NSCLC — all drugs for NSCLC →

Sponsor

Hutchison Medipharma Limited — full company profile →

Who can join

Adults 18 to 75, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fruquintinib/Placebo 5 mg, QD, orally administered under fasting conditions for 3 consecutive weeks followed by one-week off to evaluate the survival benefit of patients with advanced non-squamous NSCLC treated with Fruquintinib.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
Zhang Y, Zou JY, Wang Z, Wang Y. · · 2019 · cited 55× · PMID 31496821 · DOI 10.2147/cmar.s215533
Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review.
Su S, Wu YL. · · 2017 · cited 19× · PMID 28784178 · DOI 10.1186/s13045-017-0514-z
Pericyte signaling via soluble guanylate cyclase shapes the vascular niche and microenvironment of tumors.
Zhu J, Yang W, Ma J, He H, et al · · 2024 · cited 17× · PMID 38528180 · DOI 10.1038/s44318-024-00078-5
AIMedGraph: a comprehensive multi-relational knowledge graph for precision medicine.
Quan X, Cai W, Xi C, Wang C, et al · · 2023 · cited 7× · PMID 36856726 · DOI 10.1093/database/baad006
Efficacy and Safety of Fruquintinib-Based Treatment in Patients with Refractory Bone and Soft Tissue Sarcoma after Developing Resistance to Several TKIs: A Multicenter Retrospective Study.
Yang C, Li B, Dong S, Xu J, et al · · 2024 · cited 1× · PMID 39030807 · DOI 10.1111/os.14163
Profile of Fruquintinib in the Management of Advanced Refractory Metastatic Colorectal Cancer: Design, Development and Potential Place in Therapy
Syaj S, Saeed A. · · 2024
Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?
Mecca C, Bertaglia V, Novello S. · · 2019 · PMID 35117068 · DOI 10.21037/tcr.2018.08.23

Verify or expand the search:

Other trials of Fruquintinib

Trials testing the same drug.

NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
NCT07510932 — Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients · Phase 2 · not yet recruiting
NCT07446465 — FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectab · Phase 4 · not yet recruiting
NCT07124858 — Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metast · NA · not yet recruiting
NCT07235293 — A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorecta · Phase 2 · recruiting

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Hutchison Medipharma Limited trials

Trials by the same sponsor.

NCT05509699 — Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
NCT05318820 — A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manuf · EARLY_PHASE1 · completed
NCT05277454 — Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT · Phase 1 · unknown
NCT05015608 — Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification · Phase 3 · active not recruiting
NCT05029635 — Phase III Study on HMPL-523 for Treatment of ITP · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02691299 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hutchison Medipharma Limited
Last refreshed: 12 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02691299.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing